Research News on Hormonal Therapy
-
Zoladex May Help Reduce Risk of Recurrence
After surgery and other treatments for hormone-receptor-positive early-stage breast cancer in premenopausal women, treatment with the hormonal therapy medicine Zoladex (chemical name: goserelin) can lower the risk of the cancer coming back and improve overall prognosis.
-
Protective Tamoxifen May Lead to Earlier Diagnosis of Hormone-Receptor-Negative Cancer
Women at high risk who took tamoxifen and developed hormone-receptor-NEGATIVE breast cancer had the cancer diagnosed earlier compared to women who didn't take tamoxifen. (Tamoxifen doesn't reduce the risk of hormone-receptor-negative breast cancer.)
-
Nexavar May Make Metastatic Cancers Start Responding to Hormonal Therapy Again
A preliminary study suggests that a targeted therapy may be able to make hormone-receptor-positive breast cancers that have stopped responding to hormonal therapy start responding again.
-
Arimidex Doesn’t Seem to Cause Thinking or Memory Problems
A small study shows that women who took the aromatase inhibitor Arimidex (chemical name: anastrozole) for 2 years didn't have any more thinking and memory problems than women who took a placebo pill for 2 years.
-
Zometa Helps Keep Bones Strong During Hormonal Therapy
Zometa helps keep bones strong in pre-menopausal women getting hormonal therapy to treat hormone-receptor-positive, early-stage breast cancer.
-
Breast Cancer May Come Back Even Many Years After Treatment
A new study shows that breast cancers that are hormone-receptor-positive and later-stage are more likely to come back later than 5 years after diagnosis and treatment compared to cancers that are hormone-receptor-negative and early-stage.
-
Zometa May Reduce Recurrence Risk
New research suggests that Zometa, a bone-strengthening medicine, may help lower the risk of breast cancer coming back in premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer who aren't being treated with chemotherapy.
-
Femara After Five Years of Tamoxifen Reduces Recurrence Risk
Taking the aromatase inhibitor Femara (chemical name: letrozole) after taking tamoxifen for 5 years reduced the risk of the breast cancer coming back (recurrence), compared to not taking Femara after tamoxifen, even when Femara was started up to 7 years after tamoxifen.
-
High Estrogen Levels May Lead to Recurrence
Women diagnosed with early-stage breast cancer that came back (recurred) had higher blood estrogen levels than women diagnosed with early-stage breast cancer that didn't come back.
-
Tamoxifen Plus Removing Ovaries Improves Survival for Premenopausal Women
Removing the ovaries and taking tamoxifen after breast cancer surgery had benefits for premenopausal women shows a new study done in Vietnam and China.
